| Literature DB >> 29359916 |
Syed R Ali, Zhiqing Liu, Miroslav N Nenov, Oluwarotimi Folorunso, Aditya Singh, Federico Scala, Haiying Chen, T F James, Musaad Alshammari1, Neli I Panova-Elektronova, Mark Andrew White, Jia Zhou, Fernanda Laezza.
Abstract
Protein-protein interactions (PPI) offer unexploited opportunities for CNS drug discovery and neurochemical probe development. Here, we present ZL181, a novel peptidomimetic targeting the PPI interface of the voltage-gated Na+ channel Nav1.6 and its regulatory protein fibroblast growth factor 14 (FGF14). ZL181 binds to FGF14 and inhibits its interaction with the Nav1.6 channel C-tail. In HEK-Nav1.6 expressing cells, ZL181 acts synergistically with FGF14 to suppress Nav1.6 current density and to slow kinetics of fast inactivation, but antagonizes FGF14 modulation of steady-state inactivation that is regulated by the N-terminal tail of the protein. In medium spiny neurons in the nucleus accumbens, ZL181 suppresses excitability by a mechanism that is dependent upon expression of FGF14 and is consistent with a state-dependent inhibition of FGF14. Overall, ZL181 and derivatives could lay the ground for developing allosteric modulators of Nav channels that are of interest for a broad range of CNS disorders.Entities:
Keywords: CNS drug discovery; Fibroblast growth factor 14 (FGF14); minimal functional domains; neurochemical probes; peptidomimetics; protein:protein interaction (PPI); voltage-gated sodium channels (Nav1.6)
Mesh:
Substances:
Year: 2018 PMID: 29359916 PMCID: PMC6033619 DOI: 10.1021/acschemneuro.7b00399
Source DB: PubMed Journal: ACS Chem Neurosci ISSN: 1948-7193 Impact factor: 4.418